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Abstract
Rationale, aims and objectives Disparities in haemodialysis outcomes among centres
have been well-documented. Besides, attempts to assess haemodialysis results have been
based on non-comprehensive methodologies. This study aimed to develop a comprehensive
methodology for assessing haemodialysis centres, based on the value of health care. The
value of health care is defined as the patient benefit from a specific medical intervention per
monetary unit invested (Value = Patient Benefit/Cost). This study assessed the value of
health care and ranked different haemodialysis centres.
Method A nephrology quality management group identified the criteria for the assess-
ment. An expert group composed of stakeholders (patients, clinicians and managers) agreed
on the weighting of each variable, considering values and preferences. Multi-criteria
methodology was used to analyse the data. Four criteria and their weights were identified:
evidence-based clinical performance measures = 43 points; yearly mortality = 27 points;
patient satisfaction = 13 points; and health-related quality of life = 17 points (100-point
scale). Evidence-based clinical performance measures included five sub-criteria, with
respective weights, including: dialysis adequacy; haemoglobin concentration; mineral and
bone disorders; type of vascular access; and hospitalization rate. The patient benefit was
determined from co-morbidity–adjusted results and corresponding weights. The cost of
each centre was calculated as the average amount expended per patient per year.
Results The study was conducted in five centres (1–5). After adjusting for co-morbidity,
value of health care was calculated, and the centres were ranked. A multi-way sensitivity
analysis that considered different weights (10–60% changes) and costs (changes of 10% in
direct and 30% in allocated costs) showed that the methodology was robust. The rankings:
4-5-3-2-1 and 4-3-5-2-1 were observed in 62.21% and 21.55%, respectively, of simula-
tions, when weights were varied by 60%.
Conclusions Value assessments may integrate divergent stakeholder perceptions, create a
context for improvement and aid in policy-making decisions.
Introduction
Since the emergence of dialysis as a new therapy for chronic renal
failure in the mid-1960s, the need for haemodialysis has presented
a challenge for health services around the world. Europe alone has
more than 180 000 patients on haemodialysis in 4000 centres [1],
and haemodialysis costs range between €30 000 and 47 000 per
patient per year [2–5]. The variability in achieving therapeutic
goals across centres has been associated with the heterogeneous
quality of care [6]. Although there is concern about outcomes and
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costs, most attempts to assess haemodialysis results are based on
non-comprehensive methodologies (which do not simultaneously
consider a wide-ranging set of meaningful results, such as quality
of life, patient satisfaction and costs), or biased methodologies
(which do not include the perspective of stakeholders, such as
patients or managers) [7–9].
Evidence-based medicine has limitations. Approaches to
improving patient care have been identified, but the systems for
measuring outcome vary markedly among studies. Moreover, the
most common quality measures for haemodialysis, such as haemo-
globin (Hb) levels and dialysis dose, may explain only 15% of the
variability in morbidity and mortality [10]. This limitation sug-
gests that a new approach, which considers outcomes from a
broader perspective, is needed to evaluate health care delivery.
The value of health care is a concept that can maximize favour-
able outcomes for stakeholders and society and integrate their
frequently conflicting interests. Here, ‘value’ is defined as the
benefit achieved when patients receive a specific medical interven-
tion per monetary unit invested [11]. The benefit of the interven-
tion should be based on outcome, rather than on process; process
is largely related to tactics and is not relevant to patients. The
actual value of health care delivered by each dialysis facility is
connected to a comprehensive set of outcomes and the cost of
operation. There is a need for a methodology that can integrate the
perspectives of all stakeholders (principally patients, but also cli-
nicians and managers) to establish relevant outcomes that would
provide a more accurate, comprehensive assessment of the treat-
ment [12]. On approach to integrating these perspectives is to use
Multi-criteria Decision Analysis (MCDA) methodologies, such as
the Weight Sum Model (WSM). This approach can capture stake-
holder preferences and inform health care decisions, based on a
value matrix framework [13]. To our knowledge, no previous study
has assessed value of health care in treatments for end-stage renal
disease.
The Quality Management Group of the Spanish Society of
Nephrology designed the present study to reduce disparities and to
contribute to achieving the best possible outcomes for patients and
the community. The study objective was to develop a methodology
for assessing the value of health care delivered by haemodialysis
centres according to a comprehensive, feasible set of outcomes.
Methods
This study was designed to develop a value of health care assess-
ment of haemodialysis. In developing the methodology, different
groups contributed, including the Quality Management Group
(QM-G), an Expert Group (EG), the Centres that collected the data
and the Analysis Group. Figure 1 shows concisely the action
sequence of each group, their composition, methodology, out-
comes and relationships.
Quality management group
In October 2007, a QM-G meeting was held to develop the pre-
selected outcomes. The QM-G, composed of five nephrologists,
searched the literature to identify indicators commonly used for
Figure 1 Groups involved in the study. The group composition, methodology, outcomes and sequence of activities are shown with their input and
output relationships.
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assessing haemodialysis centres and to pre-select a set of out-
comes. Two reviewers independently searched the literature
(Medline, EMBASE and clinical guidelines reports), selected the
relevant papers and shared the full-text articles with the entire
QM-G, which then determined the pre-selected outcomes by con-
sensus. The criteria for determining the pre-selected outcomes
were that they had to address the stakeholder perspective, be
comprehensive and be based mainly on outcomes, rather than on
process. The QM-G decided to include a set of clinical perfor-
mance measures in the pre-selected outcomes; however, the con-
sensus required that assessments of clinical results should be based
on how closely they were related to morbidity, mortality and the
availability of modifiable therapeutic resources. The pre-selected
evidence-based clinical performance measures fit essentially into
clinical guideline recommendations that are graded as level 1, and
supported by the quality of evidence as A and B.
According to the concept of value, the haemodialysis cost was
considered for every centre. In 2007, the QM-G, supported by an
accounting expert, created an accounting database, specifically
designed for the purpose of the study, in Excel® (Microsoft Cor-
poration, Redmond, WA) to record micro-costing of haemodialy-
sis treatment.
Expert group
The EG was composed of nine individuals, three patients, three
clinicians and three managers who represented the haemodialysis
stakeholders. The requirements for the different constituents of the
EG were: patients must have been on haemodialysis for at least 3
years and must have served as coordinators for renal patient
organizations; the clinicians must have been of recognized prestige
and has ample experience – one of these is a nephrologist, one a
haemodialysis nurse and one an internal medicine specialist; the
clinical managers were selected for three different specialties –
economic, medical and health services researcher. A regulated
methodology was defined for ensuring the appropriate EG com-
position [14].
The first task of the EG was to define a comprehensive set of
outcomes from haemodialysis treatment, based on the previous
pre-selected outcomes. This set of outcomes was selected with a
Nominal Group Technique (November 2007).
The EG members identified an outstanding set of haemodialysis
outcomes, or criteria, according to their perceptions and prefer-
ences. The group agreed to assess the results by considering four
categories: evidence-based clinical performance measures; mortal-
ity; health-related quality of life (HRQoL), as a patient-reported
outcome measure; and patient satisfaction with the facility, as a
patient-reported experience measure.
Evidence-based clinical performance measures
The most relevant clinical measures included dialysis adequacy
(Kt/v) [15], Hb concentration [16], serum calcium (Ca), serum
phosphorous (P) [17], type of vascular access [18] and the hos-
pitalization rate [19]. The hospitalization rate was selected as a
surrogate marker for assessing morbidity. These measures were
considered sub-criteria for assessing evidence-based clinical
performance.
Mortality
In haemodialysis, mortality is a key outcome in its own right; it
reflects both measurable and immeasurable quality aspects. To
avoid random variation due to low incidence of an outcome, we
evaluated the 2-year mortality.
Health-related quality of life
We decided to measure the HRQoL with the Medical Outcomes
Study Short Form 36-item health survey (SF-36). This question-
naire captures eight dimensions of HRQoL, grouped into two
component summaries: the Physical Component Summary and the
Mental Component Summary. The SF-36 is valid and sensitive
[20]; it was also validated in Spanish, and it is the most widely
used instrument for evaluating HRQoL in haemodialysis treat-
ment. The SF-36 results were associated with hospitalization and
mortality in patients that received dialysis; the rating scale ranged
from 0 to 100 points.
Patient satisfaction
We implemented a survey that had been transculturally adapted by
the QM-G, based on the Quality of Care in Dialysis Center Ques-
tionnaire [21]. The Spanish version of the questionnaire has shown
appropriate internal consistency for the quality of care assessment
(Cronbach’s alpha 0.86). The questionnaire analysed four dimen-
sions: doctor (seven items), nurse (eight items), treatment (eight
items) and facilities (eight items). The last page of the question-
naire included a visual analog scale, ranging from 0 to 100, which
we used for the purpose of the study.
Weighting process
The second task of the EG was to perform the process of weighting
the criteria and sub-criteria with the MCDA methodology (Decem-
ber 2010) [22]. The members of the EG settled on the weighting of
each variable or criteria of each outcome to build a MCDA value
matrix. We previously described the group methodologies for the
MCDA and the WSM [14].
In the initial weighting process, each group member distributed
100 points among the four criteria; this was followed by a debate
period to discuss differences in opinions. The EG conducted a total
of three rounds of weighting, separated by two debate periods.
This process allowed the construction of the value matrix frame-
work, according to the WSM. As a result, the means of the final
weighted outcomes were: evidence-based clinical performance
measures = 43; yearly mortality = 27; patient satisfaction = 13;
and HRQoL = 17. The statistical results showed high intra-agent
agreement (agents were patients, clinicians and managers) and
high within-EG agreement (the EG as a whole was evaluated with
a Chi-squared Pearson test; P = 0.841; contingency coefficient,
P = 0.841). The details of the EG procedure and results were
previously published [14]. The values determined in the present
study were normalized proportionally to a range of 0 to 100 for
clarity.
Subsequently, the EG distributed 43 points in the category of
evidence-based clinical performance measures among the sub-
criteria based on a simplified WSM: each sub-criterion was
E. Parra et al. Value-based assessment for dialysis
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assigned a single or double weight. The EG performed this task in
a single round to complete the MCDA value matrix. The points
were distributed in equal parts (single weights), with the exception
of vascular access, which required double weighting. Therefore,
the normalized, rounded weightings at the end of the process were:
dialysis adequacy = 7 points; haemoglobin concentration = 7;
mineral and bone disorder = 7 (serum Ca = 3.5; serum P = 3.5);
hospitalization rate = 7; and type of vascular access = 15.
Centres
Centre enrollment
During 2007, the QM-G sent an email to all centres that typically
collaborated with the group to invite them formally to participate
in the study. All centres that voluntarily accepted were included in
this study. We determined that the number of centres that agreed to
participate voluntarily was sufficient to achieve the aim of the
study. In November 2007, , the EG provided the selected outcome
variables to every centre with the directive that each centre would
collect the appropriate data starting in 2008.
Data collection
In November 2008, we determined the eligibility of cross-
sectional data for the evidence-based clinical performance meas-
ures, HRQoL, patient satisfaction and morbidity. To be included in
the analyses, the questionnaires (HRQoL and patient satisfaction)
from each centre had to meet a patient response rate of 80%, and
missing values in the clinical measures and morbidity could not
exceed 5% for each centre. Prospective data were collected for
mortality from December 2008 to November 2010.
Cost measurement
The accounting department of each centre prospectively collected
the data during the financial year of 2008. All centres included the
same items and allocation criteria; therefore, costs were compa-
rable among centres. Direct costs, based on invoices, included:
staff, consumables, inpatient and outpatient pharmacy, and food.
Allocated costs, based on assignments, included: laboratory, diag-
nostic imaging, patient transport, management, health care equip-
ment and maintenance, and cleaning. The numbers of patients and
haemodialysis sessions carried out throughout 2008 were prospec-
tively recorded. This micro-costing approach allowed each centre
to average the total cost, defined as the € expended per patient per
year. Hospital admission and vascular access costs were not used
to assess value, because these costs were estimated based on the
inter-centre average costs; therefore, these costs were not appro-
priate for identifying differences between centres. The procedure
and results of the cost analysis were published previously [23].
Patient morbidity
A modified Charlson co-morbidity index was collected for each
patient. This index was used to adjust for differences in morbidity
among centres.
Analysis group
The analysis group was composed of two nephrologists, two stat-
isticians and two multi-criteria analysts. The aim of the analysis
group was to perform statistical and multi-criteria analyses to
determine the patient benefit and the value assessment.
Patient benefit
The results from each haemodialysis centre were aggregated into a
weighted sum, which was defined as the patient benefit. To obtain
the patient benefit in each centre, all criteria were considered. The
score for each criterion was proportional to the centre’s adjusted
co-morbidity results. First, the overall centre score, or patient
benefit, was calculated as the sum of the individual scores for each
criteria and sub-criteria, according to the WSM. Then, the patient
benefit results were normalized. Thus, hypothetically, in a centre
where 100% of patients underwent autologous vascular access
(criterion score = 15), the score assigned to that sub-criterion
would be 15 (15 × 1.00) for the centre. For a continuous variable,
such as cumulative survival, we used the average 2-year survival
recorded for each centre; thus, hypothetically, in a centre where
90% of patients survived (criterion score = 27), the score assigned
to that sub-criterion would be 24.3 (27 × 0.90) for the centre.
Value
Finally, the value of health care for each centre was calculated as
follows: Value of Health Care = Patient Benefit/Cost. The value
delivered by each centre was obtained by dividing the patient
benefit by the average haemodialysis cost (€) at each centre, multi-
plied by 10 000 (€ per patient per year × 10 000).
According to standard practice for quality measure reporting,
we adjusted the value of health care for the case mix, based on
demographics and co-morbidity data. We also conducted a multi-
way sensitivity analysis to explore the value of health care results
by considering the key parameters under the most favourable and
the most unfavourable conditions.
Statistical analysis
Patient demographic and clinical characteristics for each centre
were summarized with descriptive statistics. Crude comparisons
among centres were conducted with the X2 test or the Fisher test
for categorical variables. We also used the analysis of variance test
or the Kruskal–Wallis test, depending on the fulfillment of the
required statistical assumptions. The same procedures were used
to compare outcomes between groups.
The centre indicators were adjusted for demographic and clini-
cal factors, such as age, sex and Charlson index. Generalized linear
mixed models were constructed with these variables as fixed
effects and the centre as a random effect. For dichotomous
responses, we used the binomial distribution, and for continuous
responses, we used the normal distribution. The effect of the centre
was checked for significance with the likelihood ratio test, assum-
ing that it comprised a mixture of X2 distributions. For comparing
cumulative survival after adjustments, first, we used Cox regres-
sion models to perform cumulative survival analyses, and then,
these models were extended by considering the centre a random
effect. Rates were estimated based on all fixed and random effect
estimates, and for cases where the random effect variance was
estimated to be zero, the same rate was assigned for all centres.
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The adjusted indicators (rates and means) derived from the
mixed models ranged from 0 to 100, where 100 was the most
favourable value. The hospitalization rate was converted to a non-
hospitalization rate to provide positive values. Therefore, to con-
struct the patient benefit of the centre, we summed the indicators
for each item, adjusted by its weight, as assigned by the EG.
The statistical package R 2.13.1 was used for statistical analy-
ses. Specifically, we used libraries lme4, survival and Coxme to fit
the mixed models.
To account for the uncertainty in weights and costs, we per-
formed a simple sensitivity analysis. In this analysis, the weights
and cost of each criterion were randomly perturbed at a specified
time by a pre-established percentage, and the impact of variation
on the rank order was assessed. We considered 10 000 simulations,
where the criteria and sub-criteria weights were randomly changed
to represent 10–60% of variability; simultaneously, we randomly
changed the direct costs by 10%, and the allocated costs by 30%.
The analysis was performed with software developed specifically
for this simulation, based on the Delphi XE5 integrated develop-
ment environment.
Results
Six centres volunteered to participate in the study. One was not
included in the analysis because only 47% of patients answered the
HRQoL questionnaire; thus, it did not meet the minimum require-
ment of 80% response rate. The remaining five centres met all
requirements and were included in the analysis. Centres 1, 2, 4 and
5 were rural, and centre 3 was urban. Centres 1–3 were integrated
into regional hospitals, and centres 4 and 5 were satellite units.
Centres 1 and 2 were public and provided direct haemodialysis
services (not for profit), and centres 3–5 were state-subsidized (for
profit).
A total of 220 patients were included in the study. Patient
characteristics for each centre are given in Table 1. The centres
were not significantly different in demographic or clinical features,
including co-morbidity (time on haemodialysis and Charlson
index).
Table 2 shows the percentage of patients in each centre that
achieved the evidence-based clinical performance criteria. The
Kt/v values were above 1.4 in the majority of the patients (>70%)
in all centres, except Centre 3. The percentage of patients with
functioning autologous arteriovenous fistula (AAVF) was above
70% in all centres, except in Centre 1. Similar rates and means
were found after adjusting for patient demographics and
co-morbidity (Table 3). Significant differences were observed
among centres. For example, dialysis adequacy (Kt/v) was
achieved about 20% less frequently in Centre 3 than in the other
centres (P = 0.003). Also, Centre 2 achieved significantly better
patient satisfaction than the other centres (P = 0.043). The patient
benefit was evaluated with adjusted statistics, based on the weights
assigned by the EG (Table 3). In a 100-point scale, scores ranged
from 65.97 points (Centre 3, which had the lowest scores for
dialysis adequacy and serum phosphorous) to 72.59 points (Centre
4, which had relatively low hospitalization and mortality rates, the
best serum phosphorous levels, and the highest percentage of
patients with functioning AAVF).
The value delivered among these five centres ranged from 15.56
(Centre 1, which reflected the highest cost), to 20.47 (which
reflected the best patient benefit and intermediate cost).
Table 4 summarizes the sensitivity analysis. The centre rankings
of 4-5-3-2-1 and 4-3-5-2-1 were very stable; they remained con-
sistent in approximately 63 and 24% of the simulations, respec-
tively. Combined, those rankings appeared in 89.88% of
simulations when the weights were varied by 30%. All simulations
indicated that centres 2 and 1 delivered the lowest value.
Table 1 Demographic and clinical characteristics of patients in each centre (C1-C5)
C1 C2 C3 C4 C5 P-Value
n (%) 41 (18.6) 37 (16.8) 47 (21.4) 54 (24.5) 41 (18.6)
Gender (men), n (%) 25 (61.0) 22 (59.5) 31 (66.0) 34 (63.0) 27 (65.9) 0.964†
Age, mean (SD) 67.7 (13.9) 68.4 (13.0) 67.5 (14.7) 64.3 (14.6) 67.8 (15.3) 0.643‡
Months on HD*, mean (SD) 47.6 (41.2) 43.7 (40.4) 43.2 (41.5) 50.0 (52.3) 57.3 (59.5) 0.837§
Charlson Index, mean (SD) 7.78 (3.25) 7.68 (2.40) 7.11 (2.06) 7.55 (3.09) 7.21 (3.02) 0.864§
Renal diseases, n (%)
Unknown 3 (7.3) 4 (10.8) 13 (27.7) 14 (25.9) 6 (14.6)
Glomerular 9 (22) 11 (29.7) 2 (4.3) 4 (7.4) 5 (12.2)
Interstitial 5 (12.2) 4 (10.8) 2 (4.3) 5 (9.3) 4 (9.8)
Polycystic kidney 6 (14.6) 1 (2.7) 4 (8.5) 7 (13) 4 (9.8)
Vascular-hypertensive 5 (12.2) 9 (24.3) 11 (23.4) 8 (14.8) 11 (26.8)
Diabetes nephropathy 5 (12.2) 5 (13.5) 12 (25.5) 11 (20.4) 5 (12.2)
Others 8 (19.5) 3 (8.1) 3 (6.4) 5 (9.3) 6 (14.6)
*HD: Haemodialysis.
†X2 test.
‡Analysis of variance test.
§Kruskal–Wallis test.
Renal disease was not analysed for significant differences between groups, due to the small number of patients in each category.
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Discussion
Our study supported the notion that haemodialysis centres could
be assessed according to the value generated for patients and
society. The value arises from a meaningful set of outcomes, based
on a valid, reliable methodology that reflects the preferences of the
principal agents involved in the therapy. The value of the health
care delivered by haemodialysis centres should be relevant to
stakeholders. This evaluation may lead to substantial opportu-
nities; for example, it may create a context for treatment improve-
ments, process innovations, oversight administration, pay for
performance, public reporting and transparency, and health care
improvements. The value assessment could also support policy
makers in allocating scarce health care resources to maximize care
and promote a healthy society.
The results of our study were easily interpreted. Centre 4 deliv-
ered the highest value, because it achieved better outcomes for
each monetary unit invested. The overall result was that the highest
patient benefit (72.59) that could be achieved at the lowest cost
provided the greatest value. Although small number of centres
included in this study did not allow generalization of the results, it
was notable that the three centres that provided the most value
were state subsidized, and not the public centres, which provided
direct service. The results can be easily understood by patients,
haemodialysis staff, managers and policy makers. Thus, to
increase their value, haemodialysis centres must improve the
patient benefit, reduce costs, or both.
Hypothetically, a properly selected haemodialysis indicator and
reliable measures of stakeholder values and priorities would allow
construction of a mathematical formula that could be included in
the value matrix, and the centre results could be analysed accord-
ing to that measure. The interpretation would be straightforward,
transparent, comprehensive, consistent, reproducible, acceptable
to stakeholders, useful for benchmarking and focused on centre
improvement; however, the actual utility of this approach, based
on values and preferences, merits careful assessment. The com-
plexity of medicine demands a mixture of multidimensional out-
comes to evaluate the results of health interventions, which should
integrate evidence-based and preference-based approaches.
The value methodology encourages clinicians to produce cir-
cumstances that are most relevant to patients. However, the value
perceived by the patient does not necessarily always relate to
evidence-based medicine; for example, value also includes patient
satisfaction with the centre. Consequently, the methodology
requires interdisciplinary participation, and it should integrate dif-
ferent points of view, beliefs and experiences.
The MCDA methodology incorporated several assumptions
regarding the criteria. First, it assumed preferential independence;
that is, it assumed that the decision could be made by using only
the criteria on which the alternatives differ. Second, it assumed a
trade-off condition, where adding weight to one criterion should
be compensated by reducing the weight given to other criteria. If
two hypothetical centres had equal outcomes, except for the dialy-
sis dose (e.g., 80% vs. 70% adequacy), and the 1-year survival
(e.g., 70% vs. 80%, respectively), the decision ranking could be
established based on these differences, because the weight
assigned to the dialysis dose was less than the weight assigned to
the 1-year survival (7% vs. 27%); therefore, the second centre
Table 2 Outcomes achieved for each centre and statistical comparisons
Centre
Comparison
P-valueC1 C2 C3 C4 C5
Evidence-based clinical performance measures, n (%)
Kt/v ≥ 1.4 28 (70.0) 29 (85.3) 22 (51.2) 46 (85.2) 36 (87.8) <0.001†
Hb 11-13 g/dl* 21 (51.2) 23 (62.2) 23 (51.1) 33 (61.1) 23 (56.1) 0.745†
Ca 8.4–10 mg/dl 35 (85.4) 32 (86.5) 37 (82.2) 45 (83.3) 29 (70.7) 0.363†
P 2.5-4.5 mg/dl 19 (46.3) 17 (45.9) 18 (40.0) 32 (59.3) 17 (41.5) 0.324†
Functioning AAVF 19 (46.3) 27 (73.0) 33 (71.7) 42 (77.8) 31 (75.6) 0.011†
1-year hospitalization rate 20 (48.8) 20 (54.1) 19 (40.4) 16 (29.6) 11 (26.8) 0.045†
Mortality; % (SD)
2-year cumulative survival 67.7 (7.4) 58.4 (8.2) 62.1 (7.3) 78.5 (6.1) 74.1 (7.1) 0.264§
Health related quality of life (HRQoL); Mean (SD)
MCS from SF-36 53.1 (14.6) 46.8 (12.5) 46.3 (15.8) 49.1 (15.1) 51.5 (15.4) 0.393‡
PCS from SF-36 31.7 (9.5) 33.0 (7.4) 32.7 (10.3) 35.4 (10.0) 36.0 (9.2) 0.340‡
Patient satisfaction; Mean (SD)
DCQ 91.6 (10.3) 97.6 (6.0) 88.4 (18.5) 87.2 (16.4) 86.8 (12.5) 0.018‡
*According to the recommendations at the moment data were collected.
†X2 test.
‡Analysis of variance test.
§Kaplan–Meier log-rank test.
AAVF, Autologous arteriovenous fistula; Ca, Serum calcium; DCQ, Quality of Care in Dialysis Centre Questionnaire; Hb, Haemoglobin concentration;
Kt/v, Dialysis adequacy was calculated with the single pool Daugirdas II method; MCS, Mental component summary from SF-36 Questionnaire; P,
Serum phosphorous; PCS, Physical component summary from SF-36 Questionnaire.
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would exhibit higher value. The MCDA provided a valid method-
ology, supported by complex sources full of details and speakers.
However, there are different methodologies that can incorporate
the stakeholder views, such us the Delphi technique. Nevertheless,
we suggest that the MCDA is best-suited to the purpose, because
the MCDA includes a face-to-face discussion group, and the inter-
action among participants may enrich their learning, knowledge
and reasoning methods. The MCDA can achieve valuable out-
comes, and in generating the patient benefit, it unites stakeholder
interests [13,23,24].
Porter [11] suggested that measuring costs at the individual
level, rather than averaging them, could increase accuracy.
However, in a homogeneous process like haemodialysis, that
policy may not be necessary; it could increase transaction costs,
Table 3 Outcomes for each centre, adjusted for demographics (age and gender) and co-morbidity features (months on haemodialysis and
Charlson index)
Outcomes Weight Adjusted rates Comparison
(%) C1 C2 C3 C4 C5 LR§ P-value
Evidence-based clinical performance criteria 43
Kt/v ≥ 1.4 7 72.91 84.16 56.73* 85.61 86.70 10.79 0.003
Hb 11-13 g/dl‡ 7 56.80 56.80 56.80 56.80 56.80 0.00 1.000
Ca 8.4–10 mg/dl‡ 3.5 81.70 81.70 81.70 81.70 81.70 0.00 1.000
P 2.5-4.5 mg/dl 3.5 46.96 46.83 45.47 51.12 45.86 0.23 0.762
Functioning AAVF 15 57.07 73.16 71.18 75.73 73.62 2.66 0.184
Non-hospitalization rate (1 year)† 7 56.82 54.56 59.63 65.90 65.93 1.09 0.438
Mortality 27
Cumulative survival (2 years) 27 78.40 70.60 74.20 86.80 83.70 0.58 0.596
Health related quality of life (HRQoL) 17
MCS from SF-36 Mean‡ 8.5 49.65 49.65 49.65 49.65 49.65 2.82 0.169
PCS from SF-36 Mean‡ 8.5 33.85 33.85 33.85 33.85 33.85 0.00 1.000
Patient satisfaction 13
DCQ Mean 13 91.24 94.54* 89.15 88.22 87.85 5.41 0.043
Patient Benefit (PB) 66.25 67.61 65.97 72.59 71.28
Cost (€ per patient per year) 42 574 39 289 32 872 35 461 35 294
Direct cost 34 247 31 044 22 174 26 497 26 350
Allocated cost 8 327 8 246 10 698 8 964 8 945
Value (PB/cost) × 10 000 15.56 17.21 20.07 20.47 20.20
*P < 0.05.
†Values were converted to positive values (100-value), which reflect the non-hospitalization rates.
‡Estimate for the random effect with variance equal to zero.
§LR: Likelihood ratio test for models with and without random effects.
AAVF, Autologous arteriovenous fistula; Ca, Serum calcium; DCQ, Quality of Care in Dialysis Centre Questionnaire; Hb, Haemoglobin concentration;
Kt/v, Dialysis adequacy calculated with the single pool Daugirdas II method; MCS, Mental component summary from SF-36 Questionnaire; P, Serum
phosphorous; PCS, Physical component summary from SF-36 Questionnaire.
Table 4 Multi-way sensitivity analysis of
estimated centre values; the weights and
costs (direct and allocated) were changed
simultaneously to evaluate the frequency of
centre ranking and the best and worst
values estimated for each centre
Change Centre ranking (frequency %) Centre
%weight* 4-5-3-2-1 4-3-5-2-1 3-4-5-2-1 Scenario C1 C2 C3 C4 C5
10 [10; 30] 64.40 27.04 8.56 Best 18.18 20.16 24.09 24.17 23.85
Worst 13.55 14.98 17.12 17.63 17.40
20 [10; 30] 64.63 25.90 9.47 Best 18.20 20.22 24.02 24.24 23.90
Worst 13.45 14.82 16.96 17.45 17.22
30 [10; 30] 63.99 25.89 10.12 Best 18.69 20.54 24.77 24.83 24.45
Worst 13.28 14.66 16.80 17.12 16.91
40 [10; 30] 63.75 24.15 12.10 Best 18.98 20.75 24.73 25.12 24.77
Worst 13.14 14.47 16.41 17.12 16.93
50 [10; 30] 62.95 22.67 14.38 Best 18.89 20.88 24.81 25.04 24.66
Worst 12.87 14.44 16.43 16.82 16.61
60 [10; 30] 62.21 21.55 16.24 Best 18.96 21.12 24.92 25.23 24.89
Worst 12.35 13.99 16.12 16.28 16.07
*The weights were changed from 10–60%; in all cases, the direct cost was changed by 10% and the
allocated cost was changed by 30%.
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and it would be difficult to implement in a national health service
context. We also would like to emphasize that, to achieve value,
the outcomes should reflect mainly those that matter to patients.
Therefore, we assumed that considering the weighting of all stake-
holders could achieve a more comprehensive assessment. Further-
more, we propose that holding the EG meeting and implementing
the MCDA methodology placed the members in an appropriate
environment for promoting reflection and deep understanding of
the outcome significance.
Most previous studies that analysed outcomes from several
institutions aimed to grasp the variability among geographic areas
or to consider different organizational arrangements. An example
of that type of study was the Dialysis Outcomes and Practice
Patterns Study, which collected random samples from units in
more than 20 countries [5,9]. Very few studies focused on a key
outcome of specific centres [7,8]. Alternatively, the End Stage
Renal Disease Quality Incentive Program of the U.S.A. analysed
several key quality measures, including patient-reported experi-
ence measures, and they linked a portion of the payment awarded
to centres based on their outcomes (it was a pay-for-performance
strategy, or value-based purchasing program). The UK renal reg-
istry constitutes an important advance in this area. It is currently
establishing routine assessment of patient-reported outcome and
experience measures (the strategy has shifted from working ‘for’
patients to working ‘with’ patients); however, it continues to
ignore the cost, which is a key outcome, according to the concept
of value. Moreover, no previous study has attempted to put
together a comprehensive patient benefit, which could result in
better decision-making in qualifying centres. Patient benefit can
enable patient participation in health care decisions and encourage
managers and staff to improve the quality of health care. The
patient benefit instrument also allows parsing the patient benefit
into different indicators for more accurate evaluations, which
could facilitate the implementation of targeted activities to
improve centre quality.
To our knowledge, no previous study has used a similar meth-
odology to assess the value of other specific processes involved in
health care. To that end, this approach, with appropriate modifica-
tions, could be tested in other health care domains.
This study included a small number of centres, which prevented
the generalization of results. However, the main objective of the
study was to develop an instrument to measure the value delivered;
therefore, the overall approach represents a significant advance in
value assessment methodology. There is no generally accepted
questionnaire for assessing patient satisfaction in haemodialysis
centres in the Spanish language. Furthermore, there is no consen-
sus in Europe about which specific instrument should be recom-
mended to measure patient-reported experience. This lack of
standardization constitutes a limitation of this study, and it also
limits the extension of this methodology to other areas. A recent
expert consensus meeting in Europe has declared that more work
was needed to resolve this issue [25]. When the cost measurement
is based on averages, it may require some adjustment, when
centres are not comparable in the extent of morbidity. This
problem may be resolved by either calculating individual costs or
calculating a cost coefficient related to morbidity. Also, the EG and
the weighting structure we described may not be applicable to
other cultural or socio-economic settings; therefore, we encourage
testing these components before implementing the approach else-
where. We are currently attempting to validate this key point by
repeating the MCDA procedure in different intra- and inter-
cultural groups, and simultaneously, by corroborating results with
two different methodologies (WSM and the Analytic Hierarchy
Process). Despite the limitations of this value assessment
approach, we consider it a useful framework for future investiga-
tions related to value insights in a variety of homogeneous pro-
cesses. Finally, although this is a rational approach for assessing
centres, it requires further testing to determine whether it provides
any advantages over other evaluation systems.
Our results supported the notion that value can be assessed in
haemodialysis centres based on a comprehensive set of outcomes,
which include meaningful clinical results, mortality, HRQoL,
patient satisfaction and costs. This evaluation may integrate diver-
gent stakeholder perceptions and interests, create context and
incentives for quality improvements and facilitate policy-making
decisions. Despite the rationality of the instrument, it requires
further testing to determine the possible advantages of this value
assessment over other evaluation systems.
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